Regulation of appetite, satiation, and body weight by enteroendocrine cells. Part 2: Therapeutic potential of enteroendocrine cells in the treatment of obesity

Hormone Research in Paediatrics

Volumn 83, Issue 1, 2015, Pages 11-18

  Posovszky, Carsten ^a   Wabitsch, Martin ^b  

^a University Outpatient Clinic for Pediatric Gastroenterology   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Appetite; Enteroendocrine cells; Obesity; Satiation; Taste receptors

Indexed keywords

GASTROINTESTINAL HORMONE; PREBIOTIC AGENT;

APPETITE; BARIATRIC SURGERY; BODY WEIGHT; ENTEROENDOCRINE CELL; FOOD INTAKE; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; INTESTINE FLORA; LIFESTYLE MODIFICATION; NONHUMAN; NUTRIENT; OBESITY; PRIORITY JOURNAL; REVIEW; SATIETY; TREATMENT INDICATION; WEIGHT CHANGE; ANIMAL; EATING; PATHOPHYSIOLOGY; PHYSIOLOGY; WEIGHT REDUCTION;

ANIMALS; APPETITE; BODY WEIGHT; EATING; ENTEROENDOCRINE CELLS; HUMANS; OBESITY; SATIATION; WEIGHT LOSS;

EID: 84924232251     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000369555     Document Type: Review

References (55)

1. Casazza K, Fontaine KR, Astrup A, Birch LL, Brown AW, Bohan Brown MM, Durant N, Dutton G, Foster EM, Heymsfield SB, McIver K, Mehta T, Menachemi N, Newby PK, Pate R, Rolls BJ, Sen B, Smith DL Jr, Thomas DM, Allison DB: Myths, presumptions, and facts about obesity. N Engl J Med 2013; 368: 446-454.
2. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
3. Le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR: Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243: 108-114.
4. Overton HA, Fyfe MC, Reynet C: GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 2008; 153(suppl 1):S76-S81.
5. Cani PD, Hoste S, Guiot Y, Delzenne NM: Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr 2007; 98: 32-37.
6. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, De Backer F, Neyrinck AM, Delzenne NM: Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009; 90: 1236-1243.
7. Parnell JA, Reimer RA: Prebiotic fibres dosedependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats. Br J Nutr 2012; 107: 601-613.
8. Everard A, Cani PD: Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 2013; 27: 73-83.
9. Roth CL, Reinehr T: Roles of gastrointestinal and adipose tissue peptide in childhood obesity and changes after weight loss due to lifestyle intervention. Arch Pediatr Adolesc Med 2010; 164: 131-138.
10. Hellstrom PM: Satiety signals and obesity. Curr Opin Gastroenterol 2013; 29: 222-227.
11. Posovszky C, Wabitsch M: Regulation of appetite, satiation, and body weight by enteroendocrine cells. Part 1: characteristics of enteroendocrine cells and their capability of weight regulation. Horm Res Paediatr DOI: 10.1159/000368898.
12. Cammisotto PG, Levy E, Bukowiecki LJ, Bendayan M: Cross-talk between adipose and gastric leptins for the control of food intake and energy metabolism. Prog Histochem Cytochem 2010; 45: 143-200.
13. Cammisotto P, Bendayan M: A review on gastric leptin: the exocrine secretion of a gastric hormone. Anat Cell Biol 2012; 45: 1-16.
14. Moss A, Kunze D, Wabitsch M: Evidencebased therapy guideline of the German Working Group on Obesity in Childhood and Adolescence (in German). Bundesgesundhbl Gesundheitsforsch Gesundheitsschutz 2011; 54: 584-590.
15. Reinehr T: Lifestyle intervention in childhood obesity: changes and challenges. Nat Rev Endocrinol 2013; 9: 607-614.
16. McLean N, Griffin S, Toney K, Hardeman W: Family involvement in weight control, weight maintenance and weight-loss interventions: a systematic review of randomised trials. Int J Obes Relat Metab Disord 2003; 27: 987-1005.
17. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J: Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-1604.
18. Roth CL, Enriori PJ, Harz K, Woelfle J, Cowley MA, Reinehr T: Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 2005; 90: 6386-6391.
19. Reinehr T, Roth CL, Alexy U, Kersting M, Kiess W, Andler W: Ghrelin levels before and after reduction of overweight due to a low-fat high-carbohydrate diet in obese children and adolescents. Int J Obes (Lond) 2005; 29: 362-368.
20. Reinehr T, de Sousa G, Roth CL: Fasting glucagon-like peptide-1 and its relation to insulin in obese children before and after weight loss. J Pediatr Gastroenterol Nutr 2007; 44: 608-612.
21. Krohn K, Boczan C, Otto B, Heldwein W, Landgraf R, Bauer CP, Koletzko B: Regulation of ghrelin is related to estimated insulin sensitivity in obese children. Int J Obes (Lond) 2006; 30: 1482-1487.
22. Vos RC, Pijl H, Wit JM, van Zwet EW, van der Bent C, Houdijk EC: The effect of multidisciplinary lifestyle intervention on the pre-and postprandial plasma gut peptide concentrations in children with obesity. ISRN Endocrinol 2011; 2011: 353756.
23. Ochner CN, Gibson C, Carnell S, Dambkowski C, Geliebter A: The neurohormonal regulation of energy intake in relation to bariatric surgery for obesity. Physiol Behav 2010; 100: 549-559.
24. Cummings DE, Overduin J, Foster-Schubert KE, Carlson MJ: Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis 2007; 3: 109-115.
25. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B: Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365.
26. Laferrere B, Swerdlow N, Bawa B, Arias S, Bose M, Olivan B, Teixeira J, McGinty J, Rother KI: Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 4072-4076.
27. Hage MP, Safadi B, Salti I, Nasrallah M: Role of gut-related peptides and other hormones in the amelioration of type 2 diabetes after Roux-en-Y gastric bypass surgery. ISRN Endocrinol 2012; 2012: 504756.
28. Reinehr T, Roth CL, Schernthaner GH, Kopp HP, Kriwanek S, Schernthaner G: Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically induced weight loss. Obes Surg 2007; 17: 1571-1577.
29. Le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lonroth H, Fandriks L, Ghatei MA, Bloom SR, Olbers T: Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780-785.
30. Alam ML, Van der Schueren BJ, Ahren B, Wang GC, Swerdlow NJ, Arias S, Bose M, Gorroochurn P, Teixeira J, McGinty J, Laferrere B: Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 378-381.
31. Ashrafian H, Athanasiou T, Li JV, Bueter M, Ahmed K, Nagpal K, Holmes E, Darzi A, Bloom SR: Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev 2011; 12:e257-e272.
32. Holst JJ: Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol 2013; 13: 983-988.
33. Enc FY, Ones T, Akin HL, Dede F, Turoglu HT, Ulfer G, Bekiroglu N, Haklar G, Rehfeld JF, Holst JJ, Ulusoy NB, Imeryuz N: Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009; 296:G482-G489.
34. Rucker D, Padwal R, Li SK, Curioni C, Lau DC: Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
35. Drucker DJ: Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62: 3316-3323.
36. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE: DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255-1261.
37. Van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH: Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite, and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784-793.
38. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR: Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146: 5120-5127.
39. Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschop MH: Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 2013; 5: 209ra151.
40. McGavigan AK, Murphy KG: Gut hormones: the future of obesity treatment? Br J Clin Pharmacol 2012; 74: 911-919.
41. Cheung BM, Cheung TT, Samaranayake NR: Safety of antiobesity drugs. Ther Adv Drug Saf 2013; 4: 171-181.
42. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, Kim HH, Xu X, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM: Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 2007; 104: 15069-15074.
43. Steinert RE, Gerspach AC, Gutmann H, Asarian L, Drewe J, Beglinger C: The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Clin Nutr 2011; 30: 524-532.
44. Schonhoff SE, Giel-Moloney M, Leiter AB: Development and differentiation of gut endocrine cells. Endocrinology 2004; 145: 2639-2644.
45. Sakar Y, Duca FA, Langelier B, Devime F, Blottiere H, Delorme C, Renault P, Covasa M: Impact of high-fat feeding on basic helixloop-helix transcription factors controlling enteroendocrine cell differentiation. Int J Obes (Lond) 2014; 38: 1440-1448.
46. Duca FA, Zhong L, Covasa M: Reduced CCK signaling in obese-prone rats fed a high fat diet. Horm Behav 2013; 64: 812-817.
47. Duca FA, Sakar Y, Covasa M: Combination of obesity and high-fat feeding diminishes sensitivity to GLP-1R agonist exendin-4. Diabetes 2013; 62: 2410-2415.
48. Cani PD, Neyrinck AM, Maton N, Delzenne NM: Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagonlike peptide-1. Obes Res 2005; 13: 1000-1007.
49. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmee E, Cousin B, Sulpice T, Chamontin B, Ferrieres J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772.
50. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An obesityassociated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
51. Kalliomaki M, Collado MC, Salminen S, Isolauri E: Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr 2008; 87: 534-538.
52. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M: Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.e917.
53. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103.
54. Lecerf JM, Depeint F, Clerc E, Dugenet Y, Niamba CN, Rhazi L, Cayzeele A, Abdelnour G, Jaruga A, Younes H, Jacobs H, Lambrey G, Abdelnour AM, Pouillart PR: Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr 108: 1847-1858.
55. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, Francois P, de Vos WM, Delzenne NM, Schrenzel J, Cani PD: Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 2011; 60: 2775-2786.